General Clinical Data, All of the Analyzed T-Cell Populations and HLA-Haplotypes of the Patients Studied
| Patient No. . | Sex/ Age . | Diagnosis . | ANCA* . | Second Analysis . | Disease Activity† . | Treatment . | Subset‡ . | Percent . | HLA-DR . | DR4 Subtype . | HLA-DQ . | DQA1*-DQB1* . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M/70 | PAN | 25 | Active | Steroids | AV12CD4 | 49 | 4, 4 | 0401-0404 | 7, 8 | 0301-0301/0301-0302 | |
| BV3CD8 | 33 | |||||||||||
| BV8CD4 | 4.3 | |||||||||||
| 2 | M/46 | WG | <10 | Remission (since 8 months) | Steroids + mtx | BV8CD8 BV8CD4 | 42 29 | 4, 4 | 0401-0413 | 7, 7 | 0301-0301/0301-0301 | |
| 3 | M/68 | WG | 18 | (1) Remission | (1) None | BV8CD4 | (1) 15 | 4, 13 | 0401 | 8, 6 | 0301-0302/0103-0603 | |
| 20 | +10 months | (2) Active | (2) Steroids + cph | (2) 29 | ||||||||
| 4 | F/45 | WG | 99 | (1) Active | (1) None | BV2CD4 | (1) 50 | 14, 13 | 5, 6 | 0101-0503/0103-0603 | ||
| 15 | +4 months | (2) Active | (2) Steroids + cph | (2) 60 | ||||||||
| 5 | M/62 | WG | 23 | (1) Active | (1) Steroids + mtx | AV12CD8 | (1) 41 | 4, 4 | 0403-0404 | 7, 7 | 0301-0301/0301-0301 | |
| 26 | +2 months | (2) Active | (2) Steroids + mtx | (2) 35 | ||||||||
| BV8CD4 | (1) 9.9 | |||||||||||
| (2) 5.4 | ||||||||||||
| 61-153 | F/58 | WG | <10 | Remission (2 years) | Steroids + tms | BV8CD4 | (14.7)1-155 8.1 | 1, 3 | 5, 2 | 0101-0501/0501-0201 | ||
| 71-153 | M/66 | WG | <10 | Remission (3 years) | Steroids | BV8CD4 | (17.8)1-15510.0 | 1, 4 | 0401 | 5, 8 | 0101-0501/0301-0302 | |
| 81-153 | F/69 | WG | 17 | Remission (5.5 years) | None | BV8CD4 | (3.0)1-155 5.0 | 4 | 0401 | 7, 7 | 0301-0301/0301-0301 |
| Patient No. . | Sex/ Age . | Diagnosis . | ANCA* . | Second Analysis . | Disease Activity† . | Treatment . | Subset‡ . | Percent . | HLA-DR . | DR4 Subtype . | HLA-DQ . | DQA1*-DQB1* . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M/70 | PAN | 25 | Active | Steroids | AV12CD4 | 49 | 4, 4 | 0401-0404 | 7, 8 | 0301-0301/0301-0302 | |
| BV3CD8 | 33 | |||||||||||
| BV8CD4 | 4.3 | |||||||||||
| 2 | M/46 | WG | <10 | Remission (since 8 months) | Steroids + mtx | BV8CD8 BV8CD4 | 42 29 | 4, 4 | 0401-0413 | 7, 7 | 0301-0301/0301-0301 | |
| 3 | M/68 | WG | 18 | (1) Remission | (1) None | BV8CD4 | (1) 15 | 4, 13 | 0401 | 8, 6 | 0301-0302/0103-0603 | |
| 20 | +10 months | (2) Active | (2) Steroids + cph | (2) 29 | ||||||||
| 4 | F/45 | WG | 99 | (1) Active | (1) None | BV2CD4 | (1) 50 | 14, 13 | 5, 6 | 0101-0503/0103-0603 | ||
| 15 | +4 months | (2) Active | (2) Steroids + cph | (2) 60 | ||||||||
| 5 | M/62 | WG | 23 | (1) Active | (1) Steroids + mtx | AV12CD8 | (1) 41 | 4, 4 | 0403-0404 | 7, 7 | 0301-0301/0301-0301 | |
| 26 | +2 months | (2) Active | (2) Steroids + mtx | (2) 35 | ||||||||
| BV8CD4 | (1) 9.9 | |||||||||||
| (2) 5.4 | ||||||||||||
| 61-153 | F/58 | WG | <10 | Remission (2 years) | Steroids + tms | BV8CD4 | (14.7)1-155 8.1 | 1, 3 | 5, 2 | 0101-0501/0501-0201 | ||
| 71-153 | M/66 | WG | <10 | Remission (3 years) | Steroids | BV8CD4 | (17.8)1-15510.0 | 1, 4 | 0401 | 5, 8 | 0101-0501/0301-0302 | |
| 81-153 | F/69 | WG | 17 | Remission (5.5 years) | None | BV8CD4 | (3.0)1-155 5.0 | 4 | 0401 | 7, 7 | 0301-0301/0301-0301 |
Abbreviations: mtx, methotrexate; cph, cyclophosphamide; tms, trimethoprim-sulphamethoxazole.
At the time for CDR3 fragment analysis and/or cDNA sequencing. Values show cANCA in all cases except for patient 1, where it shows pANCA.
First (1) and second (2) analysis when appropriate.
TCR BV8 was analyzed and found to be normally expressed in CD8+ T cells of patients 1, 3, 5, 6, 7, and 8.
Only BV8+ T cells analyzed.
BV8 expression in CD4+ subsets of patients 6, 7, and 8 at 2 years, 2.5 years, and 1 year, respectively, before sequence analysis.